We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Use of Saliva for Alzheimer's Disease Diagnosis (SalivALZ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02864303
Recruitment Status : Terminated (end of the inclusion period)
First Posted : August 12, 2016
Last Update Posted : December 28, 2021
Information provided by (Responsible Party):
University Hospital, Montpellier

Brief Summary:
Although saliva is not generally regarded as one of the most interesting biological fluids, the fact that it can be sampled using simple, noninvasive methods makes it an interesting alternative to cerebrospinal fluid (CSF) or blood for diagnostic purposes. The use of salivary diagnostics is moreover increasing these past 10 years, as shown with the abundant literature as well as various clinical trials. Saliva collection which is now well standardized has the major advantage of being simple and non-invasive. An original study had already discussed possible changes in the salivary composition in Alzheimer's disease (AD). The feasibility and the potential interest of measuring saliva concentration of the amyloid peptides was reported in an article published recently. The prospect of using saliva for early diagnosis and monitoring of AD is thus of major interest and the objective of the current trial.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Mild Cognitive Impairment Other: Saliva samples Not Applicable

Detailed Description:

Saliva samples

To minimize the circadian effects, saliva specimens were all collected between 9:00 and 11:00 a.m. Prior to the sampling procedure, participants rinsed out their mouths three times with water. To induce salivary production, patients were asked to chew neutral or citric acid impregnated Salivette cotton swabs for exactly 60 seconds. Saliva specimens were centrifuged for 2 minutes at a rate of 1000 g to yield clear saliva, which was aliquoted into 500 µL samples in LoBind tubes and stored at -80°C before being analyzed.

Design of the study

Saliva sampling will be performed at V0 (M0), V1 (M12) and V2 (M24). Blood sampling will take place also in V1 (M12). The cases and the controls will be systematically reviewed 12 months after inclusion with a new saliva collection and a cognitive assessment (for cases and controls).

Amyloid peptide quantification

Levels of human endogenous Aβ40 and Aβ42 in saliva and human plasma samples are determined with human specific enzyme-linked immunosorbent assay (ELISA) (Biosource International, Invitrogen), according to the manufacturer's instructions. Briefly, 50 μl of saliva and plasma samples were added in triplicate to the microtiter wells. Detection limit of the assay was 6 pg/ml for Aβ40 and 1 pg/ml for Aβ42.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 88 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Predictive Value of the Aβ Peptides Salivary Dosage for Alzheimer's Disease Diagnosis
Actual Study Start Date : June 21, 2012
Actual Primary Completion Date : October 11, 2018
Actual Study Completion Date : October 11, 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Patients with Alzheimer disease
Saliva samples were collected on this patients
Other: Saliva samples
saliva specimens were collected using a neutral or citric acid impregnated Salivette cotton swabs on Alzheimer patients to quantify the level of amyloid peptides

Primary Outcome Measures :
  1. Aβ40 and Aβ42 [ Time Frame: 24 months ]
    Amyloid quantification using ultra sensitive immunoassays

Secondary Outcome Measures :
  1. Neuropsychologic tests [ Time Frame: 24 months ]
    Neuropsychologic questionaries assessed on the Alzheimer patients

  2. ApoE polymorphism [ Time Frame: 24 months ]
    Measure of the ApoE polymorphism by biological analyses

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men/Women;
  • Aged ≥ 55 years and 80 years;
  • Patients mild cognitive impairment (MCI), not answering either the criteria of a normal cognitive functioning or the criteria of the insanity, but meeting the criteria of diagnosis of following MCI in the term of a complete cognitive balance sheet (assessment) and according to the diagnostic procedure published by the work group on the MCI of the EADC:

    • Mnesic complaint
    • Decline of the cognitive performances with regard to the previous capacities
    • Cognitive disorders(confusions) objectified by the clinical evaluation (change of the memory and/or another cognitive sphere)
    • The cognitive change has no echo on the everyday life
    • Not dementia syndrome
  • Signature of the informed consent by the patient;
  • Subject affiliated to a national insurance scheme.

Exclusion Criteria:

  • Edentulous total or poor oral hygiene;
  • Absence of the signed informed consent;
  • Clinical and laboratory information insufficient or unavailable;
  • Patient deprived of freedom, by court or administrative order;
  • Major protected by law;
  • Presence of a contagious viral affection (HIV, hepatitis B and C);
  • Patient included in a therapeutic trial targeting the metabolism of metabolism of amyloid peptides ;
  • Patient in period of relative exclusion with regard to another protocol or for which the annual maximum amount of the 4500-compensations was reached.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02864303

Layout table for location information
Montpellier, France, 34295
Sponsors and Collaborators
University Hospital, Montpellier
Layout table for investigator information
Principal Investigator: Sylvain Lehmann, MD PhD University Hospital, Montpellier
Layout table for additonal information
Responsible Party: University Hospital, Montpellier
ClinicalTrials.gov Identifier: NCT02864303    
Other Study ID Numbers: 8835
First Posted: August 12, 2016    Key Record Dates
Last Update Posted: December 28, 2021
Last Verified: December 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by University Hospital, Montpellier:
Alzheimer's disease
Mild Cognitive Impairment
Amyloid peptides
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Cognitive Dysfunction
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cognition Disorders